Loading...
NPI 1598765166 · Oak Lawn, IL · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Amar Hamad is a hematology & oncology physician provider located in Oak Lawn, Illinois. This profile covers 56 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Amar Hamad |
| Address | 4400 W 95th St |
| City | Oak Lawn |
| State | IL |
| ZIP | 60453 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | July 26, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3M |
| Medicaid | $97.1K |
AMAR HAMAD is heavily Medicare-focused: lifetime Medicare revenue is $3M compared with $97.1K in Medicaid revenue, indicating Medicare overwhelmingly dominates this provider’s payer mix and that the practice’s scale is primarily captured in the Medicare dataset. The provider’s NPI was enumerated on 2005-07-26 (~21 years ago), indicating long tenure which is consistent with an established outpatient oncology practice.
Medicare revenue is highly concentrated in a few biologic/immunotherapy drug codes: the top 3 Medicare codes account for 79.9% of total Medicare revenue. J9271 (pembrolizumab) alone represents 56.1% of Medicare revenue ($1.7M) and J9299 (nivolumab) contributes 17.3% ($514.3K), signaling that high-cost oncology infusions are the core service driving revenue.
The provider’s billed volumes for pembrolizumab (J9271) are notable relative to national peers: 38.8K claims generating $1.7M and a national rank of #32 of 1841 (98th percentile), described in the source as “notably above typical national volume.” This places the provider among the top national users of this checkpoint inhibitor and implies a service-line specialization in high-volume immune-oncology infusions.
Other chemotherapy and infusion services form a consistent ancillary revenue stream: codes such as 96413, 96417, 96367, 96365, and add-on chemo codes appear across the Medicare and Medicaid lists, indicating routine administration of intravenous and subcutaneous antineoplastics and associated infusion management. For example, Medicare 96413 has 658 claims and appears in the 96th national percentile, supporting that infusion administration workload is significant.
Competitive standing is mixed across codes: for some services the provider is an extreme outlier or notably above peers (e.g., Medicare 99213 ranks #1528 of 457151 providers, labeled an “extreme outlier” and J9271 at the 98th percentile), while many oncology-specific drug and infusion codes are in mid-to-high national percentiles described as “typical, unremarkable volume” (e.g., J9299 at the 73rd percentile, multiple infusion/add-on codes in the 75–96th percentile range). This pattern indicates dominance in a few high-volume biologic agents alongside a typical level of other infusion and support services.
Medicaid billing is concentrated and modest in scale: the top 3 Medicaid codes account for 94.6% of Medicaid revenue, with evaluation & management visits 99213 and 99214 combining for ~79% of Medicaid revenue ($45.4K and $31.9K respectively). Medicaid activity appears largely office-based E/M encounters rather than high-cost biologic infusions, suggesting Medicaid patients comprise a different service mix or lower utilization of expensive agents compared with the Medicare population.
There is a payer-level service-line divergence: Medicare revenue is driven by high-cost oncology drugs (pembrolizumab, nivolumab) and associated imaging (78815, A9552), whereas Medicaid revenue is driven primarily by office E/M codes and chemotherapy administration (96413). This suggests the practice’s high-cost infusion business is concentrated in Medicare beneficiaries while Medicaid encounters skew to clinic visits and routine chemo administration.
Operational implications: the practice likely requires robust infusion capacity, drug procurement and cold-chain/logistics for high-volume biologics (pembrolizumab and nivolumab) and access to imaging services (PET/CT components 78815 and A9552). Given the Medicare concentration and the dominance of a small number of drug codes for revenue, the provider’s financial performance may be sensitive to utilization or reimbursement changes for these agents.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
56 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 38,800 | $40 | $1.7M |
| J9299 | Injection, nivolumab, 1 mg | 22,360 | $20 | $514.3K |
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 150 | $1,300 | $192.3K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,680 | $70 | $117.7K |
| J0897 | Injection, denosumab, 1 mg | 4,380 | $20 | $78.8K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 3,540 | $20 | $77.9K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 660 | $110 | $70.4K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 150 | $410 | $59.9K |
| J1437 | Injection, ferric derisomaltose, 10 mg | 2,200 | $20 | $37.4K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 22,500 | $1 | $22.5K |
Showing 1–10 of 56
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 56 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
56 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 2 | 110 | 11,600 | $40 | $564.2K |
| J9299 | 5 | 30 | 9,570 | $20 | $305.2K |
| J0897 | 132 | 410 | 2,520 | $20 | $90.8K |
| Q5119 | 3 | 40 | 1,970 | $20 | $50.6K |
| J1437 | 4 | 10 | 2,000 | $20 | $38.5K |
| J2506 | 55 | 70 | 320 | $80 | $32.9K |
| 78815 | 59 | 370 | 50 | $360 | $30.9K |
| J1439 | 50 | 80 | 25,500 | $1 | $30K |
| A9552 | 9 | 90 | 50 | $360 | $27.5K |
| J3490 | 90 | 140 | 50 | $210 | $19.4K |
Showing 1–10 of 56
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,260 | $40 | $45.4K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,000 | $30 | $31.9K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 290 | $50 | $15.1K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 220 | $20 | $5K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 30 | $10 | $270 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 3,610 | 14,680 | 300 | $50 | $48.7K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 64 | 150 | 170 | $50 | $39.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 3,124 | 14,190 | 280 | $20 | $38.9K |
| 99232 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a moderate level of medical decision making or… | 2,358 | 4,800 | 210 | $30 | $29.3K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 663 | 900 | 120 | $10 | $3.5K |
Other providers in the same ZIP code as Amar Hamad, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Village Of Oak Lawn | IL | Land Ambulance | $649.5K | $11.6M |
| Oda Solutions, Inc | IL | Methadone Clinic | $0 | $9.7M |
| Mazen Rachid | IL | Pediatrics Physician | $0 | $5.1M |
| Ahmed Ramaha | IL | General Practice Dentistry | $0 | $4.9M |
| Omprakash Sawlani | IL | Pediatrics Physician | $0 | $3.3M |
| Ghassan Zalzaleh | IL | Hematology & Oncology Physician | $3.1M | $149K |
| Sunil Shah | IL | Internal Medicine Physician | $256.6K | $1.6M |
| Chintan Mistry | IL | Emergency Medicine Physician | $301K | $1.5M |
| Rami Haddad | IL | Hematology & Oncology Physician | $1.2M | $219K |
| Ashraf Abourahma | IL | Cardiovascular Disease Physician | $406.9K | $731.9K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.